NSE filing, NSE: LYKALABS. Summary written from the filing by ALFA Finder's alert engine.
Lyka Labs Ltd: key numbers
- Share price
- ₹76.60
- Market cap
- ₹273.4 Cr
- Revenue (annual)
- ₹128.4 Cr
- Net profit (annual)
- ₹-10.03 Cr
- P/E (TTM)
- -30.7×Sector 48.7×
- Promoter holding
- 58.45%+0.00% QoQ
- FII holding
- 0.15%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lyka Labs Ltd
All →Lyka Labs Other Announcement
Lyka Labs filed its quarterly shareholding pattern for the period ended September 30, 2026 under Regulation 31. Promoter and public holdings are reported as of that date, with no transaction or corporate event.
Lyka Labs Management Change
Lyka Labs re-appointed Neeraj Golas as Non-Executive Independent Director for 36 months, effective 16 January 2027. The board approved it at its 30 October 2026 meeting.
- Execution
- 36 months from 16 January 2027
Lyka Labs Q2 FY27 Results: Turns Profitable, Net Profit ₹1.3 Cr
Lyka Labs approved unaudited standalone results for the half year ended 30 September 2026. The board also sought postal ballot approval for an independent director's reappointment.
- Key figure
- Net profit ₹1.3 Cr
Lyka Labs Board Meeting Date
Lyka Labs has intimated that its Board will meet on 30 October 2026 to consider Q2 FY27 unaudited financial results. No decisions or figures are reported in this prior intimation.
Lyka Labs Results Correction
Lyka Labs Limited submitted a revised press release for Q1 FY27 results to correct typographical errors. The company reported a consolidated net profit of Rs. 2.05 Crore.
Lyka Labs Annual General Meeting
Lyka Labs Limited conducted its 47th Annual General Meeting on August 10, 2026. Shareholders transacted business including the adoption of financial statements and approval of related party transactions.
Other results update announcements
All →Narayana Hrudayalaya Results Update
Narayana Hrudayalaya reported Q2 FY27 consolidated revenue of Rs 28,440 Mn, up 73% YoY. PAT rose 16.6% to Rs 3,012 Mn, with the UK acquisition boosting revenue.
Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Acme Universal Safezone 9 Results Update
Acme Universal Safezone 9 reported H1FY27 revenue up 16.09% to ₹119.93 crore. EBITDA rose 54.62% and PAT turned to ₹7.02 crore profit.
Radiowalla Network Results Update
Radiowalla Network reported H1 FY27 revenue of ₹107.93 million, up 7% year-on-year. EBITDA rose to ₹8.16 million, with an 8% margin.
Artemis Medicare Services Results Update
Artemis Medicare reported Q2 FY27 consolidated revenue up 13.2% and PAT up 3.7% year-on-year. Adjusted EBITDA rose 22.7%, with the Raipur hospital launched in July 2026.
Advait Energy Transitions Results Update
Advait Energy reported Q2 FY27 consolidated revenue of ₹220.9 crore, up 40.8%, and PAT of ₹19.18 crore, up 88.5%. Its order book reached ₹1,574.8 crore.
- Order book
- ₹1,575 Cr